Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."

Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.